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Abstract 
 
Objective:  
We present a series of 87 patients who underwent anteromesial temporal lobe 
resections for therapy refractory temporal lobe epilepsy. In addition to seizure 
outcome, we observed excessively elevated CRP-levels in this patient 
population. 
 
Methods: 
We followed 87 patients (m=39, f=48; mean age 33.73 ± 12.92, range 5-67 
years) who underwent surgery between July 2003 and November 2011. 
Seizure outcome was classified in all patients according to the ILAE-
classification by Wieser et al. (mean follow-up: 38.72 months). CRP levels were 
measured in 59 patients of the epilepsy surgery group and in a control group of 
44 consecutive patients with supratentorial tumors (22 glioblastomas, 22 
meningiomas).  
 
Results:  
Clinical benefit was seen in 96.6% of the patients (ILAE classes 1 to 4), 80.5% 
were completely seizure free (ILAE class 1). Post-OP CRP values were 
significantly higher in the epilepsy group (n=59; mean CRP peak value: 100.86 
mg/l, range: 16 – 258 mg/l) compared to the control group (n=44; mean CRP 
peak value: 36.85 mg/l, range: 0.4 – 233 mg/l) (p<0.001), but the correlation of 
mean CRP value and mean temperature peak is weak (r=0.31).  
 
Conclusions:  
Seizure outcome after surgery for temporal lobe epilepsy was excellent, CRP 
levels were excessively elevated in these patients in the absence of clinical 
infection and significantly higher compared to resections of supratentorial 
lesions.  
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Introduction 
 
The effectiveness of neurosurgical procedures in the treatment of therapy 
refractory temporal lobe epilepsy (RTLE) is well established [1].  Surgical 
options include the standard anterior temporal lobe resection (TLR) as well as a 
more selective resection of the mesial temporal lobe structures, first introduced 
by Niemeyer in 1958 as selective amygdalohippocampectomy (SAH). After the 
establishment of microsurgery by Yasargil, multiple microsurgical approaches 
for SAH have been described with the proximal transsylvian selective 
transamygdalohippocampectomy [2], the transsylvian-transcisternal mesial en 
bloc resection [3], the subtemporal approach [4], and the trans-middle temporal 
gyrus approach [5] being the most frequently used ones.  
 
C-reactive protein (CRP) is an acute-phase protein produced by hepatocytes in 
response to inflammation [6]. Although mainly used by clinicians to screen for 
infection, serum CRP physiologically rises following surgical procedures due to 
the inflammatory cascade triggered by surgical tissue damage, even in the 
absence of infection [7-9].  
 
This retrospective study was undertaken to study the observed CRP elevation 
after resection of the mesial temporal lobe structures and describes seizure 
outcome of 87 patients following SAH for RTLE.  
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Patients and Methods 
 
Patients 
We retrospectively analyzed the medical records of 87 consecutive patients 
(m=39, f=48; mean age 33.73 ± 12.92, range 5-67 years) who underwent 
surgery for RTLE between July 2003 and November 2011 at our institution. In 
73 cases, SAH was performed, an anterior 2/3 resection of the temporal lobe in 
14 cases. Mean follow-up was 38.72 months (SD 26.53 months; range 3 -106 
months). Seizure outcome was classified according to the ILAE classification by 
Wieser et al. [10].  
 
CRP measurement  
CRP was measured routinely in the plasma of all patients undergoing surgery 
pre- and postoperatively. The preoperative blood samples were collected on the 
morning of surgery at the same time. In the CRP-group, we had to exclude 28 
patients due to a lack of a suffient number of postoperative CRP levels 
(preoperative CRP level, CRP on post-OP day 1 and on 4 additional time points 
were regarded as suffient). In addition, we collected CRP values of a control 
group (n=44) consisting of 22 consecutive patients undergoing surgery for 
glioblastoma (GBM) in 2011 (m=9, f=13; mean age 58.83, range 38-84 years) 
and 22 consecutive patients undergoing surgery for meningioma in the same 
year (m=3, f=19; mean age 52.99, range 30-74 years). CRP concentrations 
(mg/l) were determined by latex-enhanced immunoturbidimetric assays (Roche 
Diagnostics, Mannheim, Germany on a Roche COBAS INTEGRA analyzer, 
Rotkreuz, Switzerland) with interassay coefficients of variation below 5%.  
 
Statistical analysis 
All statistics were performed using commercially available software SPSS (IBM 
SPSS Statistics 20).  The hypothesis tests performed were two-sided, a p value 
less than 0.05 was considered statistically significant. 
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Results 
 
Preoperative data 
 
In the group of 87 consecutive patients undergoing surgery for RTLE (m=39, 
f=48; mean age 33.73, range 5 - 67 years) - mean age at onset was 9.05 years 
(0 - 37 years) and mean duration of epilepsy before surgical treatment was 
23.83 years (2 - 53 years) – 27 of 87 patients had febrile seizures. Preoperative 
MRI diagnoses included 70 cases of hippocampal sclerosis, 1 cavernoma, 8 
gangliogliomas, 7 cases of focal cortical dysplasia, and one case of a 
suspected astrocytoma (Table 1) – 42 lesions were located on the right side, 45 
on the left. Preoperatively, 37 of 87 patients underwent intracarotid sodium 
amobarbital injection (Wada test) as presurgical physiological assessment for 
language and memory. In all cases numerous antiepileptic drugs (AEDs) (at 
least two) have been tested and failed to provide adequate seizure control. 
Before surgery, 32 patients were on a single AED, 48 patients were on a dual 
regimen, and 7 patients received 3 AEDs (Table 2). Mean preoperative CRP 
values were 4.98 mg/l (range: 0.3 - 53 mg/l) in the epilepsy surgery group as 
well as 3.63 mg/l (range: 0.3 - 31 mg/l) and 8.21 mg/l (range: 0.3 - 120mg/l) in 
the GBM and meningioma control group, respectively. Temperature profiles of 
51 patients in the CRP group (n=59) and of the control group were available 
(Figure 4). Mean preoperative temperature was 36.85°C (SD 0.37°C, range: 
36.0 – 38.0°C). 
 
Postoperative CRP values 
 
In the epilepsy surgery group (n=59, m=29, f=30; mean age=36.04 years) 
mean CRP peak value was 100.86 mg/l (range 16 – 258 mg/l). Two patients 
(3.4%) had a CRP peak above 200 mg/l, 12 patients (20.3%) had a peak higher 
than 150 mg/l. Median peak days was the 2nd postoperative day in the epilepsy 
surgery group (Figure 3).  
In the control group (n=44, m=12, f=32; mean age=55.91 years, range 38-84 
years) consisting of 22 consecutive patients undergoing surgery for 
meningioma and 22 patients undergoing surgery for glioblastoma, mean CRP 
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value was 36.85 mg/l (range 0.4 – 233 mg/l. The difference in CRP peak levels 
between the epilepsy surgery group and the control group is statistically highly 
significant (p<0.001). Mean post-operative peak temperature in the epilepsy 
surgery group was 37.65°C (SD 0.59°C, range: 36.6°C – 39.3°C).  Within the 
epilepsy surgery group the correlation between post-operative CRP peak value 
and post-operative peak temperature was weak (pearson’s correlation 
coefficient, r=0.31). When looking at post-operative CRP and seizure outcome, 
ILAE 1 patients in the CRP group (n=51) had a mean CRP peak value of 
102.28 mg/l (range: 25 – 258 mg/l) – ILAE 2-5 patients (n=8) had a mean CRP 
peak value of 91.83 mg/l (range: 16 – 168 mg/l). Differences in mean CRP 
peak value between the ILAE 1 group and the ILAE 2-5 group were not 
statistically significant (t-test; p=0.64, observed power 0.077). Furthermore, 
there was no significant difference within the CRP group between the patients 
undergoing SAH (n=48, mean CRP peak value: 102.15 mg/l, range: 16 – 258 
mg/l) and anterior 2/3 resections of the temporal lobe (n=11, mean CRP peak 
value: 95.27 mg/l, range: 35 – 173 mg/l) (t-test, p=0.67).  
 
Postoperative neurological outcome 
 
In 73 cases, SAH was performed, an anterior 2/3 resection of the temporal lobe 
in 14 cases. Post-operative histological diagnoses included 73 cases with 
hippocampal sclerosis, 6 gangliogliomas, 2 focal cortical dysplasias, 2 cases of 
astrocytoma (both WHO grade II), and 4 cases with gliosis (Table 1). 
Figure 1 shows seizure outcome according to the ILAE classification by Wieser 
et al.[10]. In 70 cases (80.5%) patients were postoperatively completely seizure 
free and no auras were observed (ILAE class 1), 3 patients (3.4%) had only 
auras, but no seizures (ILAE class 2), in 8 cases (9.2%) one to three seizure 
days per year were noted (ILAE class 3). Only 3 patients (3.4%) belonged to 
the ILAE class 4 (four seizures per year to 50% reduction of baseline seizures) 
and another 3 patients (3.4%) had less than a 50% reduction of baseline 
seizure days (ILAE class 5). At last follow-up (mean 38.72 months, range 3 -
106 months), 17 patients (19.5%) were completely off antiepileptic medications, 
in 24 cases (27.6%) the antiepileptic regimen was reduced, 42 (48.3%) patients 
stayed on the same medications, and 4 patients (4.6%) needed additional 
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medications (Figure 2) – 48 patients were on AED monotherapy (55.2%) and 
22 patients were on a polytherapeutic regimen (25.3%). Perioperative 
complications included one case (1.1%) of a left-sided hemiparesis, one case 
(1.1%) of oculomotor nerve palsy, three cases (3.4%) of wound infections and 
one case (1.1%) of a deep vein thrombosis. 
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Discussion 
 
Elevation of C-reactive protein levels 
 
Although it is known that CRP rises as a response to surgical tissue damage 
even in the absence of clinical infection [7-9] our results show that this post-
operative CRP-response is significantly stronger in patients undergoing surgery 
for RTLE compared to other intracranial neurosurgical procedures. Even 
patients undergoing extended resections and therefore suffering a greater 
amount of tissue damage, i.e. patients undergoing surgery for glioblastoma, 
have significantly lower post-operative CRP-levels. 
 
Circumventricular organs 
 
We hypothesize that this observation is due to an inflammatory response 
triggered by the circumventricular organs (CVOs). CVOs are vascularized 
structures surrounding the surface of the third and fourth ventricle; they are 
lacking a blood brain barrier and thereby providing an interface between the 
blood stream, the CSF, and the brain parenchyma [11]. Functions of the CVOs 
include participation in the homeostasis of energy metabolism, cardiovascular 
regulation, sodium and water balance, fever, vomiting, immunomodulation, and 
regulation of body temperature [11]. Unlike other sites of the CNS blood 
vessels in the CVO are fenestrated and do not express tight junction proteins 
such as cadherin-10 [12]. Thus cytokines may reach the circulation not via 
active transport mechanisms, but rather by movement through the endothelial 
cell layer. The topographical relation of the resection zone in epilepsy surgery 
and the location of the circumventricular organs is shown in Figure 5. 
 
Inflammatory response 
 
It was shown that the activation of Toll-like receptors (TLRs) on macrophage-
like cells residing in the CVOs lead to the production of pro-inflammatory 
cytokines [13]. In accordance with the danger model introduced by Matzinger 
[14], we hypothesize that tissue damage by surgical manipulation of the mesial 
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temporal lobe structures sets off damage associated molecular pattern 
molecules (DAMPs) which activate a non-infectious inflammatory response 
mainly by binding to TLRs of immunocompetent cells in the CVOs. For example 
TLR9 recognizes self-DNA and TLR3, TLR7 and TLR8 bind dsRNA or ssRNA, 
which are all released in conditions of tissue damage induced by surgery. As a 
consequence of TLR binding, cells are activated and produce pro-inflammatory 
cytokines such as IL-1, IL-6, or TNFα via MyD88 dependent mechansims. 
Those cytokines are released by the CVOs and trigger the overexpression of so 
called acute-phase proteins in the liver including an increase in the production 
of CRP [6]. We suspect that due to the anatomical proximity of the surgical 
resection side and the location of the circumventricular organs (Figure 5), the 
inflammatory response and the subsequent CRP production is more 
pronounced than in neurosurgical procedures. Another key factor leading to the 
observed inflammatory response in patients undergoing epilepsy surgery might 
be ventricular opening, which is part of the surgical strategy in epilepsy surgery 
(both TLR and SAH), but it rarely happens during tumor surgery. Opening the 
ventricles should lead to a direct release of DAMPs into the CSF and thereby 
increased concentrations of DAMPs reaching the CVOs. Binding of DAMPs to 
TLRs triggers an inflammatory response as described above, ultimately also 
leading to CRP production in the liver. In future studies it would be worthwhile 
to monitor the inflammatory response in other neurosurgical procedures with 
ventricular opening in a prospective fashion. 
 
Seizure Outcome 
 
Seizure outcome was excellent with 80.5% of the patients being completely 
seizure free with no auras (ILAE class 1) and clinical benefit was seen in 96.6% 
of the patients (ILAE classes 1 to 4) – mean follow-up was 38.72 months (SD 
26.53 months; range 3 -106 months). Different classification systems are used 
in the medical literature, but just by looking at the seizure-free patient group, 
which is for multiple reasons the most important group, our results compare 
well to the literature. There is one randomized controlled trial that compared 
seizure outcome after surgery to outcome after medical treatment [1]. In the 
surgery group of this trial, 58% of the patients were free of disabling seizures at 
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the end of 1 year, 38% were free of all seizures including auras, 10%-15% had 
little or no improvement compared to 8% being free of disabling seizures in the 
medical group [1]. Clinical outcome after surgery for temporal lobe epilepsy has 
also been extensively reviewed by Engel et al. [15].  Seizure outcome after 
anteromesial temporal lobe resections (not differentiating between SAH and 
tailored anterior temporal lobe resections) of 21 retrospective analyses yielded 
1769 patients of whom 1150 (65%) were free of disabling seizures, 372 (21%) 
were improved, and 347 (14%) were not improved. Only one of these centers 
reported on auras as well and consequently found 45.9% of the patients to be 
completely seizure free. In another meta-analysis by Téllez-Zenteno et al. the 
proportion of long-term seizure-free patients in 40 studies (n=3895) after 
temporal lobe surgery was 66% [16]. 
Our favorable outcome is not only due to some special surgical approach, but 
to a rather restrictive patient selection. The group of patients reported on in this 
study was evaluated in a center that initiated its presurgical epilepsy program 
with these patients starting in 2003. Therefore, only patients with concordant 
findings from neurophysiological, neuropsychological, imaging studies and 
invasive studies predicting post-surgical seizure control were admitted to 
epilepsy surgery. 
Surgical complications in our series including neurological morbidity and 
perioperative surgical complications were comparable to the literature review by 
Engel et al. [15].  
Postoperative pharmacotherapy after surgery for temporal lobe epilepsy in our 
group is similar to a report by Bien et al. were in a group of 148 patients with a 
mean follow-up of 4.8 years, 44.6% of the patientes were seizure-free and 
8.8% were free of AEDs, 55.4% received monotherapy, and 35.8% were on 
more than one AED [17].  
The mean duration of epilepsy before surgery of 23.83 years (2-53 years) in our 
series is well comparable to the medical literature. Lowe et al. showed that in a 
series of 76 patients the mean duration of epilepsy before surgery was 23.0 
years (range 2.9 - 46.9 years) and that there was no difference in the mean 
duration of epilepsy between patients with good seizure outcome (mean 
duration 22.4 years) and patients with poor seizure outcome (mean duration 
24.3 years) (p=0.49)[18]. Since there is increasing evidence in the medical 
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literature in the recent years suggesting that surgery for RTLE is not only 
effective, but also superior to medical treatment, Choi et al. investigated 
whether the mean duration of epilepsy before surgery is decreasing due to 
faster referral and earlier decisions to perform surgery. In a retrospective 
analysis 213 of a single institution, no difference in the mean duration of 
epilepsy in a group of 83 patients treated between 1996 and 1999 (mean 
duration: 22.6 years), a group of 65 patients operated between 2000 and 2003 
(mean duration: 22.4 years), and a group of 65 patients between 2004 and 
2007 (mean duration: 21.1 years)[19]. 
. 
 
Limitations 
 
We are aware of some notable limitations of our study. For one, this is a single-
center analysis in a retrospective fashion. Also, the levels of pro-inflammatory 
cytokines such as IL-1, IL-6, or TNFα were not measured in our patient 
population. Further studies should not only measure the levels of pro-
inflammatory cytokines but also compare the inflammatory response after 
epilepsy surgery to other neurosurgical procedures in a prospective fashion.  
 
 
 
Conclusions 
 
Besides excellent seizure outcome our study shows that postoperative CRP 
levels in patients undergoing surgery for RTLE were significantly higher 
compared to the CRP levels following neurosurgical resections of supratentorial 
mass lesions. This observation may be related to the close anatomical 
proximity of the resection site to the circumventricular organs and the 
subsequent inflammatory response triggered by this tissue damage. Further 
studies should not only measure the levels of pro-inflammatory cytokines but 
also compare the inflammatory response after epilepsy surgery to other 
neurosurgical procedures in a prospective fashion.  
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Figures 
 
 
 
 
Figure 1: Seizure outcome according to the ILAE classification by Wieser et al. [10] 
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Figure 2: Postoperative changes in antiepileptic medications at last clinical follow-up 
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Figure 3: Kinetics of C-reactive protein (CRP) [mg/l]  
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Figure 4: Temperature [°C] profile of 51 patients undergoing surgery for temporal 
lobe epilepsy compared to the two control groups. EPI = epilepsy surgery group; 
GBM = glioblastoma 
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Figure 5: Illustration of the topographical relation of the resection zone to the 
circumventricular organs. SFO = subfornical organ; OVLT = organum vasculosum 
laminae terminalis; NH = neurohypophysis; AP = area postrema; SCO = 
subcommissural organ; Pl = pineal gland; sAHE = selective 
amygdalohippocampectomy; 2/3 TLR = anterior 2/3-resection of the temporal lobe; 
ChPl= choroid plexus 
